This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (91)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Keith Krasinski, MD; William Borkowsky, MD

JAMA. 1989;261(17):2512-2516.

Abstract
The development of measles vaccination recommendations for immunodeficient children infected with human immunodeficiency virus requires assessment of disease risk and the risks and benefits of vaccination. Measles in 4 such children resulted in 3 severe pneumonias and 1 death despite previous immunization in 2. Antibody to measles as determined by enzyme-linked immunosorbent assay was present in 3 (12.5%) of 24 children studied retrospectively and developed in only 2 (25%) of 8 children immunized and followed up prospectively. The sera of 9 of 24 children had antibody when tested by sensitive hemagglutination inhibition. Measles developed in 2 of 6 children who had negative enzyme-linked immunosorbent assay results and positive hemagglutination inhibition results. No adverse consequences of measles immunization were detected. Although the immunogenicity of measles vaccine in children infected with human immunodeficiency virus was low and vaccine failure occurred, the apparent safety provides the rationale for immunization in the face of a potentially fatal disease. Since neither documented immunization nor low-level antibody guaranteed immunity to measles, we recommend passive postexposure immunoglobulin prophylaxis for all children infected with human immunodeficiency virus.

(JAMA. 1989;261:2512-2516)

Author Affiliations
From the Department of Pediatrics, New York (NY) University Medical Center.

Footnotes
Reprint requests to Department of Pediatrics, New York University Medical Center, 550 First Ave, New York, NY 10016 (Dr Krasinski).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Immune Containment and Consequences of Measles Virus Infection in Healthy and Immunocompromised Individuals
Permar et al.
CVI 2006;13:437-443.
FULL TEXT  

Morbidity Among Human Immunodeficiency Virus-1-Infected and -Uninfected African Children
Taha et al.
Pediatrics 2000;106:77e-77.
ABSTRACT | FULL TEXT  

Measles Immunization in HIV-Infected Children
Committee on Infectious Diseases and Committee on
Pediatrics 1999;103:1057-1060.
ABSTRACT | FULL TEXT  

Use of Licensed Vaccines for Active Immunization of the Immunocompromised Host
Pirofski and Casadevall
Clin. Microbiol. Rev. 1998;11:1-26.
ABSTRACT | FULL TEXT  

A Search for Persistent Measles, Mumps, and Rubella Vaccine Virus in Children With Human Immunodeficiency Virus Type 1 Infection
Frenkel et al.
Arch Pediatr Adolesc Med 1994;148:57-60.
ABSTRACT  

Safety and Immunogenicity of High-Dose Edmonston-Zagreb Measles Vaccine in Children With HIV-1 Infection: A Cohort Study in Kigali, Rwanda
Lepage et al.
Arch Pediatr Adolesc Med 1992;146:550-555.
ABSTRACT  

Severe Measles in Immunocompromised Patients
Kaplan et al.
JAMA 1992;267:1237-1241.
ABSTRACT